KZR Kezar Life Sciences Inc
Price (delayed)
$4.6
Market cap
$33.61M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$11.49
Enterprise value
$8.04M
Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule
Highlights
The EPS is up by 18% year-on-year and by 13% since the previous quarter
The net income has grown by 18% YoY and by 13% from the previous quarter
KZR's revenue has dropped by 100% year-on-year
Kezar Life Sciences's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of KZR
Market
Valuations
Earnings
Shares outstanding
7.31M
Market cap
$33.61M
Enterprise value
$8.04M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.29
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$90.61M
Net income
-$83.74M
EBIT
-$82.14M
EBITDA
-$81.1M
Free cash flow
-$74.24M
Per share
Balance sheet
Liquidity
EPS
-$11.49
EPS diluted
-$11.49
Free cash flow per share
-$10.18
Book value per share
$16.02
Revenue per share
$0
TBVPS
$19.85
Total assets
$144.68M
Total liabilities
$27.77M
Debt
$16.18M
Equity
$116.92M
Working capital
$117.16M
Debt to equity
0.14
Current ratio
6.76
Quick ratio
6.51
Net debt/EBITDA
0.32
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-48.7%
Return on equity
-58.7%
Return on invested capital
-60.3%
Return on capital employed
-66.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KZR stock price
How has the Kezar Life Sciences stock price performed over time
Intraday
2%
1 week
-11.03%
1 month
-19.44%
1 year
-46.7%
YTD
-31.55%
QTD
-5.74%
Financial performance
How have Kezar Life Sciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$90.61M
Net income
-$83.74M
Gross margin
N/A
Net margin
N/A
KZR's revenue has dropped by 100% year-on-year
Kezar Life Sciences's gross profit has shrunk by 100% YoY
The company's operating income rose by 19% YoY and by 13% QoQ
The net income has grown by 18% YoY and by 13% from the previous quarter
Growth
What is Kezar Life Sciences's growth rate over time
Valuation
What is Kezar Life Sciences stock price valuation
P/E
N/A
P/B
0.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 18% year-on-year and by 13% since the previous quarter
The price to book (P/B) is 83% less than the 5-year quarterly average of 1.6 and 30% less than the last 4 quarters average of 0.4
KZR's equity is down by 38% year-on-year and by 13% since the previous quarter
KZR's revenue has dropped by 100% year-on-year
Efficiency
How efficient is Kezar Life Sciences business performance
The company's return on invested capital fell by 37% YoY
KZR's ROE is down by 28% YoY
The return on assets has declined by 22% year-on-year but it is up by 2.8% since the previous quarter
Dividends
What is KZR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KZR.
Financial health
How did Kezar Life Sciences financials performed over time
The quick ratio fell by 43% YoY and by 10% QoQ
KZR's current ratio is down by 42% year-on-year and by 12% since the previous quarter
The debt is 86% less than the equity
KZR's debt to equity is up by 40% year-on-year and by 8% since the previous quarter
KZR's equity is down by 38% year-on-year and by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.